Autopsy report · NCT02765165
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Cause of deathFunding or business
“Business reasons not related to safety”
Life of this trial
- Ran for about 4 years 3 months before it stopped.
- 26 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Proximagen, LLC
- Sponsor type
- Industry
- Conditions
- Solid Tumors (Phase 1); Relapsed/Recurrent GBM (Phase 2)
- Interventions
- USL311; USL311; USL311; Lomustine
- Participants
- 26
- Sites
- 6
- Countries
- Spain, United States
Trials that died the same way
- Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
“Business reasons and not due to any safety concerns” - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
“Business reasons and not based on any safety concerns.” - An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension
“Business reasons unrelated to product safety” - A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
“business decision, not safety reasons.” - Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
“Business decision, not related to safety”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.